NVIDIA (NVDA) is a top pick to benefit from the AI trend, with a belief it will be "200 plus soon." For a high-conviction biotech play, consider Abivax (ABVX), which is viewed as a major long position with a price target of $200. In the weight-loss drug space, Eli Lilly (LLY) is positioned as the clear winner, while competitor Novo Nordisk (NVO) should be avoided due to weakening fundamentals. Large-cap tech stocks like Meta Platforms (META) are also strong buys, driven by successful AI integration and record financial performance. Finally, investors should avoid or consider shorting speculative quantum computing stocks, which are seen as over-hyped.

Abivax (ABVX)

• The speaker identifies Abivax as his biggest long position.
• He expresses a very bullish price target, stating, "I think Abivax is going to like 200. Maybe higher, honestly."
• He purchased the stock at $50 and notes its current price is around $72.
• A significant risk factor was mentioned: "The Abivax patent is definitely the big problem with the company. That is the one Achilles heel they have."
  • However, he later adds, "Patent will hold. I read the patent. I thought it was decent. It doesn't need to hold that long either."

Takeaways

• The speaker has a strong bullish conviction on Abivax, viewing it as a stock that could more than double from current levels.
• This is a high-conviction, high-risk play. The primary risk identified is the company's patent portfolio, which is crucial for its long-term success. Investors should be aware of this "Achilles heel."

Replimune (REPL)

• This is the speaker's third biggest long position.
• He highlights a recent successful trade: "We bought it when it failed. And now it's doubled." The stock was up 75% following news of a personnel change at the FDA.
• He believes the chance of the drug getting approved is now 50/50.
• Due to the binary (all or nothing) nature of the investment, he is considering de-risking his position: "I'll sell half. I mean I don't want to sell it. I do think they'll be approved but... It's a gamble. I'll gamble with half of it."

Takeaways

• Replimune is presented as a high-risk, high-reward biotech investment dependent on an FDA approval decision.
• The speaker's strategy illustrates a key principle for managing high-risk positions: taking some profits after a significant run-up to reduce risk, while still maintaining exposure for potential future gains.

Novo Nordisk (NVO)

• The speaker is extremely bearish on Novo Nordisk and wishes he had shorted the stock.
• The primary reason for his bearishness is intense competition from Eli Lilly's drugs, Mounjaro and Zepbound. He notes, "Munjaro has beaten Ozempic" and "Zepbound's even higher than Munjaro."
• He points to declining prescription trends for Novo's drugs (Ozempic scripts are flat) as a major warning sign that investors could have used to predict the stock's fall.
• He highlights that Novo has cut its growth guidance multiple times, from an initial 16-24% down to 13-21%, and now to 8-14%.
• His final recommendation is to "avoid Novo."

Takeaways

• The investment thesis against Novo Nordisk is based on deteriorating fundamentals, driven by losing market share to a superior competitor.
• The speaker emphasizes the importance of tracking key data points, like prescription trends ("script trends"), to get ahead of negative company announcements and stock price declines.
• Despite the stock's significant drop, he sees no reason to invest, as management has lost credibility and competitive pressures are intensifying.

Meta Platforms (META)

• The speaker is very bullish on Meta, especially after its recent earnings report.
• He was impressed by the company "knocking it out of the park" with a significant revenue beat ($76.4 billion reported vs. $73.37 billion expected).
• He notes that AI is finally benefiting Reels, which is a key growth driver for the company.
• He also highlights Mark Zuckerberg's essay on personal superintelligence, viewing it as a powerful long-term vision for the company.
• The company is demonstrating strong financial discipline, achieving record operating income while continuing to invest heavily in R&D.

Takeaways

• Meta is presented as a strong buy based on excellent financial performance, strong guidance, and a clear, ambitious vision for AI.
• The company is successfully monetizing its investments in AI through core products like Reels, driving better-than-expected growth.

NVIDIA (NVDA)

• The speaker is bullish on NVIDIA and believes the stock will be "200 plus soon."
• His bullishness is directly tied to the massive infrastructure build-out required for Artificial Intelligence.
• He specifically mentions that Mark Zuckerberg's vision for "superintelligence" at Meta is "so bullish for NVIDIA," as it will require immense computing power.

Takeaways

• NVIDIA is positioned as a primary beneficiary of the long-term AI trend.
• As major tech companies like Meta invest billions in building out their AI capabilities, NVIDIA is expected to see continued high demand for its GPUs.

Quantum Computing Stocks

• The speaker holds a bearish view on the current publicly traded quantum computing companies, calling them "shitty quantum stocks."
• He mentions he is looking to "short" them.
• Specific companies mentioned include D-Wave (QBTS), which he notes is trying to build a "real business," and IonQ (IONQ), whose co-founder was featured in a clip discussing the technology's very early and uncertain stage.
• The expert in the clip states, "we don't yet know exactly how these devices will be used in the future," highlighting the speculative nature of the field.

Takeaways

• The speaker believes the quantum computing sector is currently over-hyped and presents a potential shorting opportunity.
• While the underlying technology is promising, its commercial applications are still largely unknown and likely many years away, making current stock valuations speculative.

Sarepta Therapeutics (SRPT)

• The speaker's commentary on Sarepta is complex; he holds a "pretty full position" but is fundamentally very critical of the company.
• He expresses a bearish view on their products, stating, "Sarepta's drugs don't really work" and that the company gets "favoritism because of Duchenne," the disease it treats.
• He calls the company an "ugly duckling" that is always in the "penalty box."

Takeaways

• This is a cautionary example. The speaker holds a position but is deeply skeptical of the company's core science.
• This suggests his investment may be a short-term trade based on market sentiment or a specific catalyst rather than a long-term belief in the company's fundamentals.
• The key risk for any investor is the potential for the market to eventually agree that the company's drugs are not effective, which would severely impact the stock price.

ATYR Pharma (LIFE)

• The speaker is extremely bearish on ATYR Pharma, based on his analysis of their scientific data.
• He performs a detailed critique of one of their scientific papers, calling it a "scientific atrocity" and finding the results in animal models to be "embarrassing."
• He is highly critical of the company's approach, questioning if they even know the mechanism of their own drug.
• He dismisses bullish retail investors, stating, "I'm the predator and you're the prey."

Takeaways

• This is a strong, data-driven bearish call. The speaker believes the fundamental science behind the company is deeply flawed.
• It serves as a warning about investing in biotech companies without doing deep due diligence on the underlying science, as the risk of failure is very high.

General Market & Sector Commentary

• Cannabis Stocks: The speaker is unequivocally bearish, calling them "worthless" and something he would short. The takeaway is to avoid the sector entirely.
• UnitedHealth Group (UNH): A neutral-to-bearish view. The speaker questions paying 10 times earnings for a non-growth business and sees long-term headwinds from AI potentially lowering healthcare costs.
• Microsoft (MSFT): Very bullish sentiment following a massive earnings and revenue beat, similar to his view on Meta.
• Eli Lilly (LLY): Mentioned in the context of Novo Nordisk. Lilly is seen as the clear winner in the obesity drug market with its "dual-acting" drugs Mounjaro and Zepbound, which are "crushing" the competition.